et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9. , , ,
et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–33. , , ,
et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098–104. , , ,
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 2004; 10: 657–60. , .
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319–24. , , , , .
Chronic hepatitis B. Hepatology 2007; 45: 507–39. , .
Diagnosis, management and treatment of hepatitis C. ASSLD practice guidelines. Hepatology 2004; 39: 1147. , , , .
Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076–81. , , .
et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597–603. , , ,
et al. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999; 29: 257–63. , , ,
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25–36. , , , , , .
Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701–2. , , , , , .
Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686–7. , , , , .
Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363–5. , , , , , .
Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974–6. , , , , .
et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163–6. , , ,
et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788–9. , , ,
et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005; 52: 2519–20. , , ,
Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007; 26: 950–2. , .
Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508–9. , , , , , .
Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn’s disease. Inflamm Bowel Dis 2007; 13: 1453–4. , , .
Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718–20. , , , , , .
et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol 2008; 43: 397–401. , , ,
Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008; 14: 245–6. , , .
Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48: 448–50. , .
Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 2003; 30: 1624–5. , , , .
Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab,etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 787–91. , , , .
Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421–4. , , .
Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008; 27: 1069–71. , , .
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63(Suppl 2): ii18–24. , , .
et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107–9. , , ,
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45: 1294–7. , , , , .
et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis 2009; 3: 47–91. , , ,
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549–58. , , , , .
et al. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008; 58: 94–105. , , ,
et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67: iii2–25. , , ,
et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652–7. , , ,
et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22–6. , , ,
Lamivudine resistance and exacerbation of hepatitis B in infliximab-treatedCrohn’s disease patient. Inflamm Bowel Dis 2007; 13: 1450–1. , , .
et al. EASL International Consensus Conference on Hepatitis B. Consensus Statement. J Hepatol 2003; 39(Suppl1): S3–25. , , ,
et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 390–9. , , ,
et al. The long-term course of HCV after kidney transplantation. Transplantation 1996; 62: 1417. , , ,
Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 191–2. , .
Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800–4. , .
Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003; 98: 504–5. , , .
Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580–4. , .
Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 261–4. , , , , .
Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007; 46: 97–9. , , , , , .
Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078–82. , , , .
Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006; 54: 2335–7. , .
Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54: 361–2. , , .
Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 1102–4. , , , , , .
Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008; 47: 980–1. , .
Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006; 12: 4. , .
et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944–9. , , ,
Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353–5. , , , , .
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 104–6. , , , .
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn’s disease. Am J Gastroenterol 2007; 102: 1333–4. , , .
Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007; 26: 1127–9. , , , .
Safety of etanercept therapy in a patient with psoriasis, Down’s syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008; 22: 1514–6. , , , , , .
Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315–22. ;
Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98: 1588–93. , , , , .
Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 856–60. , , , , , .
et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 290–3. , , ,
et al. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Alimentary Pharmacol Ther 2008; 28: 742–8. , , ,
et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989; 158: 307–12. , , ,
Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093–8. , , , .
et al. Inhibition of immunoreactive tumor necrosis factor-a by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996; 174: 63–8. , , ,
et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 257–64. , , ,
Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn’s disease. Gut 2006; 55: 1670–1. , , , , , .
et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74: 197–200. , , ,
et al. Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med 2006; 166: 1783–4. , , ,
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67: 710–2. , , , , .
Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007; 13: 79–80. , , .
Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 2003; 30: 407–11. .
Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004; 150: 784–6. , , , , , .
Successful treatment with etanercept of von Zumbusch Pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008; 144: 453–6. , , .
CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49: 1–125.
Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435–78. , , .
Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986; 323: 819–22. , .
US Food and Drug Administration Center for Drug Evaluation and Research Website [Accessed July 28th 2008] (Available at: http://www.fda.gov/cder/aers/extract.htm)
et al. Disseminated herpes simplex (HSV) infection precipitating macrophage activation syndrome (MAS) in a child with systemic juvenile idiopathic arthritis (SJIA) undergoing therapy with infliximab [abstract]. Pediatr Rheumatol Online J 2003; 1: S58. , , ,
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29: 2327–9. , , , , , .
Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 540–3. , , , .
et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737–44. , , ,
Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology 2008; 217: 260–1. , .
Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26. , , , .
Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol 2009; 60: 709–10. , , , .
Development of varicella during adalimumab therapy. J Eur Acad Dermatol Venereol 2007; 21: 687–8. , , , .
An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006; 45: 999–1000. , , , .
Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 2503–4. , , .
Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004; 31: 2517–8. , , , .
et al. Cytomegalovirus colitis in a patient with Behcet’s disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912–4. , , ,
Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2006; 42: 733–4. , .
et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39: e88–94. , , ,
Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2005; 40: 1071–2. , .
Disseminated cytomegalovirus infection in Crohn’s disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1393–5. , , .
et al. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis 2007; 13: 896–902. , , ,
Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1132–5. , , , , , .
et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008; 43: 180–3. , , ,
Epstein–Barr virus and lymphoproliferative disorders after transplantation . Am J Transplant 2004; 4(Suppl 10): 59–65.
Human papillomavirus infection. Am J Transplant 2004; 4(Suppl 10): 95–100.
et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn’s disease: A meta-analysis. Gastroenterology 2008; 134(suppl1): A144. , , ,
et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621–30. , , ,
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8. , , , , .
The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–9. , .
Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol 2008; 18: 315–8. , , , .
Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 2008; 28: 475–7. , , , .
et al. Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10: 85–90. , , ,
Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 762–7. , , , , , .
et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632–6. , , ,
Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 631–63. , , .
Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009; 136: 451–8. , , , , , .
Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 598–605. , , .
Genital condylomata in a patient receiving infliximab for Crohn’s disease. Postgrad Med J 2004; 80: 358–9. , .
Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008; 216: 364–5. , , , .
Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralizing therapy. Ann Rheum Dis 2003; 62: 684. , , , .
Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16: 357–64. , , , .
et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677–92. , , ,
et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834–40. , , ,
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272–9. , , , .
et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929–36. , , ,